期刊文献+

肠内营养疗法在儿童克罗恩病治疗中的作用 被引量:4

Effectiveness of Enteral Nutritional Therapy in Children with Crohn′s Disease
原文传递
导出
摘要 至少25%的克罗恩病(CD)患者在儿童期发病,且大多患者伴体质量减轻,身高增长不良,甚至严重影响成年期最终身高,导致心理精神疾病发生。长期激素治疗可能导致显著的不良反应,这使肠内营养疗法在儿童CD(特别是活动性CD)的治疗中显得尤为重要。在欧美(尤其欧洲)国家,肠内营养被作为一线疗法。 At least 25% of individuals diagnosed patient with Crohn′s disease(CD) have onset of disease in childhood,and almost every patient with CD has nutritional impairment,such as weight loss,growth failure,even the final adult height may be impaired,sometimes psychological status of the patient may be caused.Long-term corticosteroids therapy may result in significant side effects,so the enteral nutritio-nal therapy seems to be much more suitable for pediatric CD(especially active CD).In the west,particularly in European countries,enteral nutrition is considered as the first-line of treatment for pediatric CD.
作者 彭晓康 詹学
出处 《实用儿科临床杂志》 CAS CSCD 北大核心 2011年第7期538-541,共4页 Journal of Applied Clinical Pediatrics
关键词 炎症性肠病 克罗恩病 肠内营养疗法 儿童 inflammatory bowel disease Crohn′s disease enteral nutritional therapy child
  • 相关文献

参考文献5

二级参考文献76

共引文献148

同被引文献27

  • 1Nirooshun Rajendran,Devinder Kumar.Role of diet in the management of inflammatory bowel disease[J].World Journal of Gastroenterology,2010,16(12):1442-1448. 被引量:24
  • 2Estall J,Drucker D. Glucagon-like peptide-2[J].Annual Review of Nutrition,2006,(0):391-411.doi:10.1146/annurev.nutr.26.061505.111223.
  • 3Brinkman AS,Murali SG,Hitt S. Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure[J].American Journal of Physiology-Gastrointestinal and Liver Physiology,2012,(05):G610-G622.
  • 4Uko V,Radhakrishnan K,Alkhouri N. Short bowel syndrome in children:current and potential therapies[J].Pediatric Drugs,2012,(03):179-188.
  • 5Topstad D,Marttin G,Sigalet D. Systemic GLP-2 levels do not limit adaptation after distal intestinal resection[J].Journal of Pediatric Surgery,2001,(05):750-754.
  • 6Dacambra MP,Yusta B,Sumner-Smith M. Structural determinants for activity of glucagon-like peptide-2[J].Biochemistry,2000,(30):8888-8894.
  • 7Sigalet D. Nonruminant nutrition symposium:the role of glucagon-like peptide-2 in controlling intestinal function in human infants:regulator or bystander[J].Journal of Animal Sciences,2012,(04):1224-1232.
  • 8Cheeseman CI,O'neill D. Basolateral D-glucose transport activity along the crypt-villus axis in rat jejunum and upregulation induced by gastric inhibitory peptide and glucagon-like peptide-2[J].Experimental Physiology,1998,(05):605-616.
  • 9Moran G,O'Neill C,McLaughlin J. GLP-2 enhances barrier formation and attenuates TNFα-induced changes in a Caco-2 cell model of the intestinal barrier[J].Regulatory Peptides,2012,(1-3):95-101.
  • 10Cani PD,Possemiers S,van de Wiele T. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability[J].Gut,2009,(08):1091-1103.

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部